Dosage form. Concentrate for solution for infusion.
Pharmacotherapeutic group. Antineoplastic agents. Antimetabolites. Structural analogues of pyrimidine. ATC code L01B C02.
Clinical characteristics.
Indication.
Treatment of breast cancer and rectal cancer (in the form of monotherapy or in combination with other antineoplastic agents).
Treatment of gastric cancer, head and neck cancer and pancreatic cancer.
Contraindication.
· Hypersensitivity to uracil fluoride.
· Suppression of bone marrow function, especially after radiation therapy or treatment with other anticancer drugs.
· Significant deviations in the number of formed elements in the blood.
· Bleeding.
· Stomatitis, ulcers of the mucous membranes of the mouth and gastrointestinal tract.
· Severe diarrhea.
· Severe hepatic and / or renal impairment.
· Severe infectious diseases.
· Severe exhaustion.
· Plasma bilirubin level> 85 μmol / l.
· Active vaccination should be avoided during treatment with fluoride uracil.
Method of application and dosage.
Doses and treatment regimens are determined individually depending on the patient’s condition and type of cancer, as well as depending on whether 5-fluoro uracil “Ebeve” is used as monotherapy or in combination with other treatments.
It is necessary to start treatment with 5-fluorine uracil “Ebeve” in a hospital. The total daily dose for adults should not exceed 1 g
Usually adults dose is determined per 1 kg of real patient mass, but patients with significant overweight, edema, ascites and other forms of abnormal fluid retention in the body dose is determined per 1 kg of ideal body weight.
Ebeve 5-fluoro uracil is administered by intravenous injection, intravenous infusion or intra-arterial infusion.
The following are indicative dose recommendations.
